WO2005019162A1 - Hydroxamic acid derivatives and the method for preparing thereof - Google Patents

Hydroxamic acid derivatives and the method for preparing thereof Download PDF

Info

Publication number
WO2005019162A1
WO2005019162A1 PCT/KR2004/002143 KR2004002143W WO2005019162A1 WO 2005019162 A1 WO2005019162 A1 WO 2005019162A1 KR 2004002143 W KR2004002143 W KR 2004002143W WO 2005019162 A1 WO2005019162 A1 WO 2005019162A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
carboxyamide
hydroxycarbamoyl
methyl
benzamide
Prior art date
Application number
PCT/KR2004/002143
Other languages
French (fr)
Inventor
Ho Sik Rho
Heung Soo Baek
Su Jong Kim
Su Nam Kim
Byung Geun Chae
Byoung Seok Lee
Bae Hwan Kim
Gyu Ho Choi
Eui Dong Son
Hae Kwang Lee
Hye Won Lee
Jun-Cheol Cho
Duck Hee Kim
Ih Seop Chang
Ok Sub Lee
Original Assignee
Amorepacific Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040020401A external-priority patent/KR100629712B1/en
Priority claimed from KR1020040054886A external-priority patent/KR100643511B1/en
Application filed by Amorepacific Corporation filed Critical Amorepacific Corporation
Priority to EP04774404A priority Critical patent/EP1660437B1/en
Priority to US10/595,124 priority patent/US7282522B2/en
Priority to JP2006524575A priority patent/JP4939941B2/en
Publication of WO2005019162A1 publication Critical patent/WO2005019162A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Definitions

  • the present invention relates to hydroxamic acid derivatives represented by the following formula ( I ), having anti-aging efficacy and to a method for the preparation thereof : [Formula 1]
  • Ri is or , herein, R 5 and R 6 each independently represents a hydrogen atom, an alkyl group having from 1 to 10 carbon atoms or a cyclic alkyl group having from 3 to 6 carbon atoms;
  • R 2 is CONH, NHCO, CONR 7 or NR 7 CO, herein, R 7 represents an alkyl group having from 1 to 10 carbon atoms;
  • R 4 is a hydrogen atom or an alkyl group having from 1 to 10 carbon atoms.
  • ECM extracelluar matrix
  • matrix metallo proteases such as collagenase and elastase
  • collagenase and elastase are expressed to decompose collagen and elastin, and the collagen content within the skin is reduced.
  • the reduction of collagen and elastin within the dermis leads the epidermis to be rough and to lose elasticity. That is, the skin becomes aged.
  • some materials have been developed and used.
  • retinoid such as retinol and retinoic acid has been known to be very effective in lessening skin wrinkles and improving skin elasticity (Dermatology therapy, 1998, 16, 357 ⁇ 364).
  • retinoid has some drawbacks that only a small quantity of application causes irritation to the skin and is easily oxidized in an air due to its instability, thus there are lots of limitation in using it.
  • Retinoid includes retinol, retinoic acid or its derivatives. It exhibits various biological activities. With regard to the skin, the efficacy on abnormal keratinization or on pimple was reported.
  • retinoid can inhibit the expression of elastase, with regard to the elasticity-reduction.
  • retinoid has been developed as follows: In the first stage, simple derivatives of retinol or retinoic acid were developed. As a derivative, retinyl palmitate may be exemplified. In the next, retinoid derivative including benzoic acid was developed. This derivative is named as arotinoid (J. Med. Chem, 1988, 31, 2182-2192).
  • heteroarotinoid compounds including heteroatom introduced into the . benzene ring of arotinoid, called as heteroarotinoid, have been developed (J. Med. Chem., 1999, 42, 4434-4445). Retinoid was reported to exhibit biological efficacy on the skin by interacting with the intercellullar receptor called as retinoic acid receptor (British Journal of dermatology, 1999, 140, 12-17). The structural feature of retinoid is based on tetramethyl cyclohexane, unsaturated carbon bond and carboxylic acid. Specially, carboxylic acid moiety is essential in the action of retionids and can be easily converted into an anion when interacting with the receptor (Chem. Pharm.
  • Arotinoid includes benzoic acid substituted for carboxylic acid moiety of retinoic acid. Benzoic acid moiety can be easily ionized to act as an anion. Recent studies have synthesized derivatives including various substituents for carboxylic acid moiety. These substituent-conversions are in order to maintain original efficacy of retinoid and to lessen toxicity or irritation and instability thereof. For the purpose, many studies have been conducted.
  • an object of the invention is to provide novel hydroxamic acid derivatives, which function as a retinoid to promote collagen biosynthesis and to inhibit the expression of collagenase, i.e.
  • Hydroxamic acid has been widely known as a metal chelator. Judging from the structural feature of hydroxamic acid, hydroxy group of hydroxylamine adjacent to carbonyl group forms chelation with metal cation. In additional feature, hydroxy group of hydroxylamine can be easily converted into an anion, to be used in similar to carboxylic acid.
  • the present inventors utilized these structural features of hydroxamic acid to synthesize a novel retinoid and found that it functioned as an agonist to retinoic acid receptor. Such a compound having the stricture of hydroxamic acid and functioning as a retinoid has not been reported yet.
  • the present invention relates to hydroxamic acid derivatives represented by the following formula ( I ) : [Formula 1]
  • Ri is or , herein, R 5 and Rg each independently represents a hydrogen atom, a CpCio alkyl group or a C 3 -C 6 cyclic alkyl group;
  • R 2 is CONH, NHCO, CONR 7 or NR 7 CO, herein, R 7 represents a C C 10 alkyl group;
  • the novel type of retinoid in the present invention, hydroxamic acid derivatives may be prepared by either of two methods exemplified below.
  • the method for preparing said hydroxamic acid derivatives represented by said formula ( I ) may comprise the steps of : (1) Reacting benzoic acid or adamantanecarboxylic acid with methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester, to form an amide bond; or reacting aniline or adamantamine wih monomethylterephthalate, to form an amide bond; (2) Substituting an alkyl group for amide bond of benzamide formed in said step;
  • the present hydroxamic acid derivative as a novel retinoid, may be prepared by either of two methods exemplified below.
  • the first method 1 may comprise the steps of:
  • R 7 (I) wherein, R 5 and R 6 each independently represents a hydrogen atom, a - o alkyl group or a C 3 -C 6 cyclic alkyl group; R 2 is CONH, NHCO, CONR 7 or
  • R 7 represents a C ⁇ -C 10 alkyl group
  • R 4 is a hydrogen atom or a -C ⁇ 0 alkyl group.
  • benzoic acid or adamantanecarboxylic acid may be converted to an anhydride by employing ethyl chloroformate in an equivalent ratio of 1.2.
  • a solvent employed herein may be pyridine, N-methylmo holine and the like.
  • the anhydride may be reacted with methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester, to produce a benzamide compound.
  • a solvent employed in this reaction may be pyridine, N-methylmorpholine and the like.
  • the reaction may be performed by further employing trimethylamine, in an equivalent ratio of 1.2 to methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester. Most preferably, it may be pyridine. Further, the reaction may be preferably performed at a temperature of 10 ⁇ 20°C . At a lower temperature than this, methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester may remain unreacted and it is difficult to withdraw it from the product. While, at a higher temperature than 20 ° C , the anhydride may be hydrolyzed, resulting in the decrease of the yield of the product.
  • trimethylamine in an equivalent ratio of 1.2 to methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester. Most preferably, it may be pyridine. Further, the reaction may be preferably performed at a temperature of 10 ⁇ 20°C . At a lower temperature than this, methyl 4-aminobenzoate or 4-aminopheny
  • Benzamide compound formed herein may be reacted with an alkyl halide in a solvent of N,N-dimethylformamide, to produce a benzamide compound with an alkyl group substituted for amide bond thereof.
  • sodium hydride may be employed in an equivalent ratio of 1.2 to benzamide.
  • alkyl halide may be employed in an equivalent ratio of 1.2 to benzamide.
  • an alkyl halide it may include bromomethane, bromoethane, bromopropane, bromo-isopropane, bromobutane, bromo-fert-butane and the like.
  • methylester of benzamide with or without alkyl group substituted to amide bond may be hydrolyzed to an acid.
  • the acid formed may be converted to an anhydride by employing ethyl chloroformate.
  • ethyl chloroformate may be employed in an equivalent ratio of 1.2 to the acid.
  • a solvent employed herein may be pyridine, N-methylmorpholine and the like.
  • the anhydride formed in said step may be reacted with hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride, to produce a hydroxamic acid compound.
  • a solvent employed in this reaction may be pyridine, N-methylmorpholine and the like.
  • the reaction may be performed by further employing triethylamine, in an equivalent ratio of 1.2 to hydroxylamine hydrochloride. Most preferably, it may be pyridine. Further, the reaction may be preferably performed at a temperature of 0-10 ° C . At a lower temperature than this, hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride may remain unreacted, resulting in the decrease of the yield of the product. While, at a higher temperature than this, by-products reacting with hydroxyl group of hydroxylamine or N-methyl hydroxylamine may be produced and it is difficult to withdraw it from the product.
  • triethylamine in an equivalent ratio of 1.2 to hydroxylamine hydrochloride. Most preferably, it may be pyridine. Further, the reaction may be preferably performed at a temperature of 0-10 ° C . At a lower temperature than this, hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride may remain unreacted, resulting
  • the other method 2 for preparing the present hydroxamic acid derivative may comprise the steps of:
  • R 5 and Re each independently represents a hydrogen atom, a C C ⁇ o alkyl group or a C 3 -C 6 cyclic alkyl group;
  • R 2 is CONH, NHCO, CONR 7 or NR 7 CO, herein, R 7 represents a C ⁇ -C 10 alkyl group;
  • R 4 is a hydrogen atom or a C1-C1 0 alkyl group.
  • reaction scheme 2 firstly, monomethylterephthalate may be converted to an anhydride by employing ethyl chloroformate. Then, the anhydride may be reacted with aniline or adamantamine, to produce a benzamide compound. The next reactions may be performed by the same procedure described in the reaction scheme 1.
  • Hydroxamic acid derivatives of the formula ( I ) obtained in said methods may include, but not limited hereto,
  • Hydroxamic acid derivatives of the formula ( I ) obtained in said methods is a retinoid and function as an agonist to retinoic acid receptor and, based on retinoid' s efficacy, can promote collagen biosynthesis and inhibit the expressions of collagenase, i.e. an enzyme for decomposing collagen and of elastase, i.e. an enzyme for decomposing elastin. Therefore, hydroxamic acid derivatives of the formula ( I ) provided by the present invention may be incorporated into medicines or external applications for improving skin elast city.
  • Example 2 Preparation of N- [4-(TS[-hydroxycarbamoyl phenvn [4-methylphenyl] carboxyamide Except that 4-methylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid.
  • Example 4 Preparation of N-[4-(N-hydroxycarbamoyl phenyl1 4-ethylphenyl] carboxyamide Except that 4-ethylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.4g, 39% yield) as a pale yellow solid.
  • Example 14 Preparation of N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[3-methylphenyl] carboxyamide Except that methyl 4-[(3-methylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 3 was used, the procedure described in Example 12 was performed to give the title compound (12.2g, 44% yield) as a pale yellow solid.
  • Example 15 Preparation of N-[4-(N-hydroxycarbamoyl phenyl]-N-methyl-[4-ethylphenyl] carboxyamide Except that methyl 4-[(4-ethylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 4 was used, the procedure described in Example 12 was performed to give the title compound (10.4g, 42% yield) as a pale yellow solid.
  • Example 18 Preparation of N-[4- ⁇ Sf-hvdroxycarbamoyl)phenyl]-N-methyl-[4-butylphenyl] carboxyamide Except that methyl 4-[(4-butylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 7 was used, the procedure described in Example 12 was performed to give the title compound (12. lg, 47% yield) as a pale yellow solid.
  • Example 22 Preparation of adamantyl-N-[4-( ' N-hvdroxy-N-methylcarbamoyl phenyn-N-methylcarboxyamid e Except that N-methyl hydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride, the procedure described in Example 21 was performed to give the title compound (11.4g, 39% yield) as a pale yellow solid.
  • Example 32> Preparation of N-[4-(N-hvdroxycarbamoylmethyl)phenyl] adamantyl carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 10 was performed to give the title compound (11.9g, 44%> yield) as a pale yellow solid.
  • Example 1 was performed to give the title compound (12.8g, 45% yield) as a pale yellow solid.
  • Example 38 Preparation of [4-(N-hydroxycarbamoyl phenyl]-N-[4-propylphenyl] carboxyamide Except that monomethylterephthalate and 4-propylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (11.6g, 39% yield) as a pale yellow solid.
  • Example 39 Preparation of r4-(N-hydroxycarbamoyl phenyl] -N- [4-isopropylphenyl] carboxyamide Except that monomethylterephthalate and 4-isopro ⁇ ylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (ll.lg, 41% yield) as a pale yellow solid.
  • Example 41 Preparation of [4-(N-hydroxycarbamoyl)phenyl]-N-[4-tert-butylphenyl] carboxyamide Except that monomethylterephthalate and 4-tert-butylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (12.8g, 41% yield) as a pale yellow solid.
  • Example 42 Preparation of [4-(N-hydroxycarbamoyl phenyl] -N- [3.4-dimethylphenyl] carboxyamide Except that monomethylterephthalate and 3,4-dimethylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (11.6g, 43% yield) as a pale yellow solid.
  • Example 43 Preparation of [4-(N-hydroxycarbamoyl phenyl1 -N-adamantyl carboxyamide Except that monomethylterephthalate and adamantamine were used instead of adamantanecarboxylic acid and methyl 4-aminobenzoate, the procedure described in Example 10 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid.
  • Example 47 Preparation of [4-(N-hydroxycarbamoyl phenyl]-N-methyl-N-[3-methylphenyl] carboxyamide Except that methyl 4-[(3-methylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 36 was used, the procedure described in Example 12 was performed to give the title compound (ll.Og, 39% yield) as a pale yellow solid.
  • Example 48 Preparation of [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-ethylphenyl] carboxyamide Except that methyl 4-[(4-ethylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 37 was used, the procedure described in Example 12 was performed to give the title compound (12.0g, 40% yield) as a pale yellow solid.
  • Example 49 Preparation of [4-(N-hydroxycarbamoyl phenyl] -N-methyl-N- [4-propylphenyl] carboxyamide Except that methyl 4-[(4-propylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 38 was used, the procedure described in Example 12 was performed to give the title compound (12.8g, 41% yield) as a pale yellow solid.
  • Example 51 Preparation of [4-(N-hvdroxycarbamoyl phenyl]-N-methyl-N-[4-butylphenyl] carboxyamide Except that methyl 4-[(4-butylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 40 was used, the procedure described in Example 12 was performed to give the title compound (12.0g, 40% yield) as a pale yellow solid.
  • CV-1 cells were seeded into 96-well microtiter plate at 5,000 cells per well and cultured in DMEM (Dulbecco's Modified Eagle's Media) supplemented with 2.5% fetal bovine serum. 24 Hours later, the cells were transfected with lOng of pECE-RAR ⁇ , lOng of pECE-RAR ⁇ , lOOng of reporter plasmid and lOOng of ⁇ -galactosidase-expression vector, using LipofectaminPlus (GIBCO BRL, grand island, NY).
  • collagenase production was measured with collagenase kit (commercialized by AmershamPharmacia Biotech). Firstly, the culture fluid was added to 96-well plate spread with primary collagenase antibody and then antigen-antibody reaction was performed in an incubator for 3 hours. Later, chromophore-conjugated secondary antibody was added to the 96-well plate and then reacted for 15 minutes. Then, color former was added thereto, to induce development at room temperature for 15 minutes. 1M of sulfuric acid was added to stop the reaction. The reaction solution got yellow. The color density depends on the progress of the reaction. The absorbance of the yellow 96-well plate was measured at 405nm using abso ⁇ tiometer. Collagenase expression was calculated by the following equation 1. Herein, the absorbance of the culture fluid collected from the medium with no material treated was used as a control.
  • Collagenase expression (%) (Absorbance of test group with said material treated /Absorbance of control group with no material treated)xl00
  • the fibroblastes were cultured in serum-free DMEM for 24 hours and treated for 24 hours with 10 "4 M of hydroxamic acid derivatives of Examples 1-55, retinol or retinoic acid in serum- free medium, and then the culture fluid was collected.
  • elastase production was measured with elastase kit (commercialized by AmershamPharmacia Biotech).
  • the culture fluid was added to 96-well plate spread with primary elastase antibody and then antigen-antibody reaction was performed in an incubator for 3 hours. Later, chromophore-conjugated secondary antibody was added to the 96-well plate and then reacted for 15 minutes.
  • Example 3 0.375 No irritation Example 31 0.567 No irritation Example 4 0.350 No irritation Example 32 0.375 No irritation Example 5 0.375 No irritation Example 33 0.765 No irritation Example 6 0.315 No irritation Example 34 0.678 No irritation Example 7 0.312 No irritation Example 35 0.245 No irritation Example 8 0.330 No irritation Example 36 0.456 No irritation Example 9 0.470 No irritation Example 37 0.456 No irritation Example 10 0.375 No irritation Example 38 0.567 No irritation Example 11 0.375 No irritation Example 39 0.145 No irritation Example 12 0.410 No irritation Example 40 0.546 No irritation Example 13 0.500 No irritation Example 41 0.367 No irritation Example 14 0.231 No irritation Example 42 0.987 No irritation Example 15 0.789 No irritation Example 43 0.456 No irritation Example 16 0.567 No irritation Example 44 0.678 No irritation Example 17 0.123 No irritation Example 45 0.900 No irritation Example 18 0.321 No irritation Example 46 0.345 No irritation Example 19 0.223 No irritation Example 47 0.367 No irritation Example 20 0.421 No irritation Example 48 0.468 No irritation Example 21 0.345 No irritation Example 49 0.342 No irritation Example
  • hydroxamic acid derivatives obtained in Examples 1 to 55 were confirmed to be non-irritative to the skin. These results illustrate that hydroxamic acid derivatives of the present invention have the same efficacy in improving skin elasticity as that of retinol or retinoic acid, and additionally good safety and less skin irritation, to be incorporated into skin-care external compositions for improving skin elasticity.
  • Phototoxic index (Irritation index of UV irradiation site) - (Irritation index of UV non-irradiation site)
  • hydroxamic acid derivatives obtained in Examples 1 to 55 were confirmed to have 0 of phototoxic index, which was lower value than 0.5, criterion value to be estimated as no phototoxicity.
  • Hydroxamic acid derivatives according to the present invention may be incorporated into skin-care external compositions.
  • the present composition may be formulated into, but not limited to, cosmetic compositions such as skin softners, astringents, nutrient toilet water, nutrient creams, massage creams, essences, eye creams, eye essences, cleansing creams, cleansing foams, cleansing water, packs, powders, body lotions, body creams, body oils, body essences, make-up bases, foundations, hairdyes, shampoos, hair-conditioners and body cleansers; and pharmaceutical compositions such as ointment, gels, creams, patches, and sprays.
  • each formulation may further contain bases and additives suitable for the preparation thereof, if necessary, whose kind and amount can be easily selected in this art.
  • hydroxamic acid derivatives according to the present invention can promote collagen biosynthesis and inhibit the expressions of collagenase and elastase by interacting to retinoic acid receptor. Furthermore, they do not cause skin irritation and skin toxicity, which have been drawbacks of retinoid compounds to be solved. Therefore, they can be inco ⁇ orated into medicines or skin-care external compositions for improving skin elasticity and preventing skin aging.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides hydroxamic acid derivatives represented by the following formula (I), having anti-aging efficacy and a method for preparation thereof: wherein, R1 is or, herein, R5 and R6 each independently represents a hydrogen atom, a C1-C10 alkyl group or a C3-C6 cyclic alkyl group; R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents a C1-C10 alkyl group; R3 is (CH)n-, herein, n=0 or 1; and R4 is a hydrogen atom or a C1-C10 alkyl group. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula (I) as an active ingredient.

Description

HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARAING THEREOF FIELD OF THE INVENTION
The present invention relates to hydroxamic acid derivatives represented by the following formula ( I ), having anti-aging efficacy and to a method for the preparation thereof : [Formula 1]
Figure imgf000002_0001
(I) wherein,
Ri is
Figure imgf000002_0002
or , herein, R5 and R6 each independently represents a hydrogen atom, an alkyl group having from 1 to 10 carbon atoms or a cyclic alkyl group having from 3 to 6 carbon atoms;
R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents an alkyl group having from 1 to 10 carbon atoms;
R3 is -(CH)n-, herein, n = 0 or 1; and
R4 is a hydrogen atom or an alkyl group having from 1 to 10 carbon atoms.
BACKGROUND OF THE INVENTION The skin of all living things grows aged as it grows older. In order to delay this skin aging, many efforts have been made extensively. As a result, the questions on the essence and cause of the aging have always been raised. Skin aging is classified into two kinds depending on its cause. The first is intrinsic aging that the structure of and the physiological function of the skin decline successively as aging goes on. And, the second is extrinsic aging that is caused by accumulated stress such as UV radiation. Particularly, UV radiation is well-known cause of aging. In case of the skin exposed to UV radiation for a long time, stratum corneum of the skin becomes thicker and collagen and elastin, which are main components of the skin, get denatured so that skin loses its elasticity. Thus, skin aging is accompanied by several functional and structural changes. As structural changes caused by skin aging, epidermis, dermis and hypoderm of the skin become thinner. And, dermal ECM (extracelluar matrix), which is in charge of skin elasticity and elongation, is experienced with its component's change. ECM is composed of two components, i.e. elastic fiber which amounts to 2~4% of total ECM and collagen which amounts to 70~80%. As skin aging goes on, the skin loses elasticity due to the reduction of collagen and elastin. These reductions are caused by several factors in biosynthesis. For example, matrix metallo proteases, such as collagenase and elastase, are expressed to decompose collagen and elastin, and the collagen content within the skin is reduced. The reduction of collagen and elastin within the dermis leads the epidermis to be rough and to lose elasticity. That is, the skin becomes aged. In order to suppress the reductions of collagen and elastin, which are a cause of the skin elasticity reduction, some materials have been developed and used. Specially, retinoid such as retinol and retinoic acid has been known to be very effective in lessening skin wrinkles and improving skin elasticity (Dermatology therapy, 1998, 16, 357~364). In spite of its anti-wrinkle efficacy and elasticity-improving efficacy, retinoid has some drawbacks that only a small quantity of application causes irritation to the skin and is easily oxidized in an air due to its instability, thus there are lots of limitation in using it. In order to stabilize retinoid, many studies have been conducted. However, the irritation of retinoid onto the skin, that is troubles in safety onto the skin, remains unsolved. Retinoid includes retinol, retinoic acid or its derivatives. It exhibits various biological activities. With regard to the skin, the efficacy on abnormal keratinization or on pimple was reported. And, with regard to the skin wrinkles, it has been known that it can promote collagen biosynthesis and inhibit the activity of collagenase, i.e. an enzyme for decomposing collagen (The Journal of Investigative Dermatology, 1991, 96, 975-978). In addition, retinoid can inhibit the expression of elastase, with regard to the elasticity-reduction. Up to now, retinoid has been developed as follows: In the first stage, simple derivatives of retinol or retinoic acid were developed. As a derivative, retinyl palmitate may be exemplified. In the next, retinoid derivative including benzoic acid was developed. This derivative is named as arotinoid (J. Med. Chem, 1988, 31, 2182-2192). Recently, compounds including heteroatom introduced into the . benzene ring of arotinoid, called as heteroarotinoid, have been developed (J. Med. Chem., 1999, 42, 4434-4445). Retinoid was reported to exhibit biological efficacy on the skin by interacting with the intercellullar receptor called as retinoic acid receptor (British Journal of dermatology, 1999, 140, 12-17). The structural feature of retinoid is based on tetramethyl cyclohexane, unsaturated carbon bond and carboxylic acid. Specially, carboxylic acid moiety is essential in the action of retionids and can be easily converted into an anion when interacting with the receptor (Chem. Pharm. Bull, 2001, 49, 501-503). Arotinoid includes benzoic acid substituted for carboxylic acid moiety of retinoic acid. Benzoic acid moiety can be easily ionized to act as an anion. Recent studies have synthesized derivatives including various substituents for carboxylic acid moiety. These substituent-conversions are in order to maintain original efficacy of retinoid and to lessen toxicity or irritation and instability thereof. For the purpose, many studies have been conducted.
SUMMARY OF THE INVENTION
Under these circumstances, the present inventors have conducted many studies in order to lessen skin irritation of retinoid and to provide a solution for instability in external formulations for skin care. As a result, we synthesized a novel type of retinoid, i.e. hydroxamic acid derivatives. Furthermore, we found that these hydroxamic acid derivatives had good safety to the skin and improved stability in the formulations, without skin irritation and discoloration and odorizing, caused by the conventional retinal or retinoic acid. Based on these findings, the present invention has been completed. Therefore, an object of the invention is to provide novel hydroxamic acid derivatives, which function as a retinoid to promote collagen biosynthesis and to inhibit the expression of collagenase, i.e. an enzyme for decomposing collagen and the expression of elastase, i.e. an enzyme for decomposing elastin, and to provide a method for preparing the same. Hydroxamic acid has been widely known as a metal chelator. Judging from the structural feature of hydroxamic acid, hydroxy group of hydroxylamine adjacent to carbonyl group forms chelation with metal cation. In additional feature, hydroxy group of hydroxylamine can be easily converted into an anion, to be used in similar to carboxylic acid. The present inventors utilized these structural features of hydroxamic acid to synthesize a novel retinoid and found that it functioned as an agonist to retinoic acid receptor. Such a compound having the stricture of hydroxamic acid and functioning as a retinoid has not been reported yet.
The present invention relates to hydroxamic acid derivatives represented by the following formula ( I ) : [Formula 1]
Figure imgf000006_0001
(I) wherein,
Ri is
Figure imgf000006_0002
or , herein, R5 and Rg each independently represents a hydrogen atom, a CpCio alkyl group or a C3-C6 cyclic alkyl group; R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents a C C10 alkyl group;
R3 is -(CH)n-, herein, n = 0 or 1; and t is a hydrogen atom or a -C10 alkyl group. The novel type of retinoid in the present invention, hydroxamic acid derivatives may be prepared by either of two methods exemplified below. In detail, the method for preparing said hydroxamic acid derivatives represented by said formula ( I ) may comprise the steps of : (1) Reacting benzoic acid or adamantanecarboxylic acid with methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester, to form an amide bond; or reacting aniline or adamantamine wih monomethylterephthalate, to form an amide bond; (2) Substituting an alkyl group for amide bond of benzamide formed in said step;
(3) Hydrolyzing the ester bond of benzamide or alkyl-substituted benzamide formed in said steps; and
(4) Converting the acid formed by said hydrolysis to a hydroxamic acid.
Specially, in the last step of producing a hydroxamic acid derivative, one-step processing without protective/deprotective reactions is used to increase efficiency. DETAILED DESCRIPTION OF THE INVENTION
The following is a detailed description of the present invention. The present hydroxamic acid derivative, as a novel retinoid, may be prepared by either of two methods exemplified below. The first method 1 may comprise the steps of:
(a) Reacting benzoic acid or adamantanecarboxylic acid with methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester, to produce a benzamide compound;
(b) Substituting an alkyl group for amide bond of benzamide formed in said step; (c) Hydrolyzing methylester of benzamide or alkyl-substituted benzamide compounds formed in said steps, to produce an acid; and
(d) Reacting said acid with hydroxylamine hydrochlori.de or N-methyl hydroxylamine hydrochloride, to produce a hydroxamic acid derivative. Said method of the present invention will be described in more detail by the following reaction scheme. Firstly, said method 1 may be exemplified by the following reaction scheme 1 :
[Reaction Scheme 1]
Figure imgf000008_0001
R N s — ^ Ri N j g: R7 R7
R7 (I) wherein, R5 and R6 each independently represents a hydrogen atom, a - o alkyl group or a C3-C6 cyclic alkyl group; R2 is CONH, NHCO, CONR7 or
NR7CO, herein, R7 represents a Cι-C10 alkyl group; R3 is -(CH)n-, herein, n = 0 or 1 ; and R4 is a hydrogen atom or a -Cι0 alkyl group.
In the first place, benzoic acid or adamantanecarboxylic acid may be converted to an anhydride by employing ethyl chloroformate in an equivalent ratio of 1.2. A solvent employed herein may be pyridine, N-methylmo holine and the like. Then, the anhydride may be reacted with methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester, to produce a benzamide compound. A solvent employed in this reaction may be pyridine, N-methylmorpholine and the like. Additionally, in a solvent such as N,N-dimethylformamide, methylene chloride, chloroform and the like, the reaction may be performed by further employing trimethylamine, in an equivalent ratio of 1.2 to methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester. Most preferably, it may be pyridine. Further, the reaction may be preferably performed at a temperature of 10~20°C . At a lower temperature than this, methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester may remain unreacted and it is difficult to withdraw it from the product. While, at a higher temperature than 20 °C , the anhydride may be hydrolyzed, resulting in the decrease of the yield of the product. Benzamide compound formed herein may be reacted with an alkyl halide in a solvent of N,N-dimethylformamide, to produce a benzamide compound with an alkyl group substituted for amide bond thereof. Herein, as a base, sodium hydride may be employed in an equivalent ratio of 1.2 to benzamide. Also, alkyl halide may be employed in an equivalent ratio of 1.2 to benzamide. As an alkyl halide, it may include bromomethane, bromoethane, bromopropane, bromo-isopropane, bromobutane, bromo-fert-butane and the like. Subsequently, methylester of benzamide with or without alkyl group substituted to amide bond may be hydrolyzed to an acid. Then, the acid formed may be converted to an anhydride by employing ethyl chloroformate. Herein, ethyl chloroformate may be employed in an equivalent ratio of 1.2 to the acid. A solvent employed herein may be pyridine, N-methylmorpholine and the like. Then, the anhydride formed in said step may be reacted with hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride, to produce a hydroxamic acid compound. A solvent employed in this reaction may be pyridine, N-methylmorpholine and the like. Additionally, in a solvent such as N,N-dimethylformamide, methylene chloride, chloroform and the like, the reaction may be performed by further employing triethylamine, in an equivalent ratio of 1.2 to hydroxylamine hydrochloride. Most preferably, it may be pyridine. Further, the reaction may be preferably performed at a temperature of 0-10 °C . At a lower temperature than this, hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride may remain unreacted, resulting in the decrease of the yield of the product. While, at a higher temperature than this, by-products reacting with hydroxyl group of hydroxylamine or N-methyl hydroxylamine may be produced and it is difficult to withdraw it from the product.
The other method 2 for preparing the present hydroxamic acid derivative may comprise the steps of:
(a) Reacting aniline or adamantamine with monomethylterephthalate, to produce a benzamide compound;
(b) Substituting an alkyl group for amide bond of benzamide formed in said step;
(c) Hydrolyzing methylester of benzamide or alkyl-substituted benzamide compounds formed in said steps, to produce an acid; and
(d) Reacting said acid with hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride, to produce a hydroxamic acid derivative and may be exemplified by the following reaction scheme 2: [Reaction Scheme 2]
Figure imgf000010_0001
wherein, R5 and Re each independently represents a hydrogen atom, a C Cιo alkyl group or a C3-C6 cyclic alkyl group; R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents a Cι-C10 alkyl group; R3 is -(CH)n-, herein, n = 0 or 1; and R4 is a hydrogen atom or a C1-C10 alkyl group.
As shown in the reaction scheme 2, firstly, monomethylterephthalate may be converted to an anhydride by employing ethyl chloroformate. Then, the anhydride may be reacted with aniline or adamantamine, to produce a benzamide compound. The next reactions may be performed by the same procedure described in the reaction scheme 1.
Hydroxamic acid derivatives of the formula ( I ) obtained in said methods may include, but not limited hereto,
1. N-[4-(N-hydroxycarbamoyl)phenyl] benzamide,
2. N-[4-(N-hydroxycarbamoyl)phenyl] [4-methylphenyl] carboxyamide,
3. N-[4-(N-hydroxycarbamoyl)phenyl] [3-methylphenyl] carboxyamide,
4. N-[4-(N-hydroxycarbamoyl)phenyl][4-ethylphenyl] carboxyamide, 5. N-[4-(N-hydroxycarbamoyl)phenyl][4-propylphenyl] carboxyamide,
6. N-[4-(N-hydroxycarbamoyl)phenyl] [4-isopropylphenyl] carboxyamide,
7. N-[4-(N-hydroxycarbamoyl)phenyl][4-butylphenyl] carboxyamide,
8. N-[4-(N-hydroxycarbamoyl)phenyl] [4-tert-butylphenyl] carboxyamide,
9. N- [4-(N-hydroxycarbamoyl)phenyl] [3 ,4-dimethylphenyl] carboxyamide, 10. N-[4-(N-hydroxycarbamoyl)phenyl] adamantyl carboxyamide,
11. adamantyl-N-[4-(N-hydroxy-N-methylcarbamoyl)phenyl] carboxyamide,
12. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-benzamide,
13. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-methylphenyl] carboxyamide, 14. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[3-methylphenyl] carboxyamide, 15. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-ethylphenyl] carboxyamide,
16. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-propylphenyl] carboxyamide,
17. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-isopropylphenyl] carboxyamide,
18. N- [4-(N-hydroxycarbamoyl)phenyl] -N-methyl- [4-butylphenyl] carboxyamide,
19. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-te/ -butylphenyl] carboxyamide, 20. N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[3,4-dimethylρhenyl] carboxyamide,
21. N-[4-(N-hydroxycarbamoyl)phenyl] adamantyl-N-methylcarboxyamide,
22. adamantyl-N-[4-(N-hydroxy-N-methylcarbamoyl)phenyl]-N-methylcarboxyamid e,
23. N-[4-(N-hydroxycarbamoylmethyl)phenyl] benzamide,
24. N-[4-(N-hydroxycarbamoylmethyl)phenyl] [4-methylphenyl] carboxyamide,
25. N- [4-(N-hydroxycarbamoylmethyl)phenyl] [3 -methylphenyl] carboxyamide,
26. N-[4-(N-hydroxycarbamoylmethyl)phenyl] [4-ethylphenyl] carboxyamide, 27. N-[4-(N-hydroxycarbamoylmethyl)ρhenyl][4-propylphenyl] carboxyamide,
28. N-[4-(N-hydroxycarbamoylmethyl)phenyl][4-isopropylphenyl] carboxyamide,
29. N-[4-(N-hydroxycarbamoylmethyl)phenyl] [4-butylphenyl] carboxyamide,
30. N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-tert-butylphenyl] carboxyamide,
31. N- [4-(N-hydroxycarbamoylmethyl)phenyl] [3 ,4-dimethylphenyl] carboxyamide,
32. N-[4-(N-hydroxycarbamoylmethyl)phenyl] adamantyl carboxyamide, 33. 2-[4-(adamantylcarbonylamino)phenyl]-N-hydroxy-N-methylacetamide,
34. [4-(N-hydroxycarbamoyl)phenyl]-N-benzamide,
35. [4-(N-hydroxycarbamoyl)phenyl] -N- [4-methylphenyl] carboxyamide, 36. [4-(N-hydroxycarbamoyl)phenyl] -N- [3 -methylphenyl] carboxyamide, 37. [4-(N-hydroxycarbamoyl)phenyl]-N-[4-ethylphenyl] carboxyamide, 38. [4-(N-hydroxycarbamoyl)phenyl]-N-[4-propylphenyl] carboxyamide, 39. [4-(N-hydroxycarbamoyl)phenyl] -N- [4-isopropylphenyl] carboxyamide,
40. [4-(N-hydroxycarbamoyl)phenyl]-N- [4-butylphenyl] carboxyamide,
41. [4-(N-hydroxycarbamoyl)phenyl]-N-[4-ter?-butylphenyl] carboxyamide, 42. [4-(N-hydroxycarbamoyl)phenyl]-N-[3,4-dimethylphenyl] carboxyamide,
43. [4-(N-hydroxycarbamoyl)phenyl]-N-adamantyl carboxyamide,
44. N-adamantyl [4-(N-hydroxy-N-methylcarbamoyl)phenyl] carboxyamide,
45. [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-benzamide,
46. [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-methylphenyl] carboxyamide,
47. [4-(N-hydroxycarbamoyl)ρhenyl]-N-methyl-N-[3-methylphenyl] carboxyamide,
48. [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-ethylphenyl] carboxyamide, 49. [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-propylphenyl] carboxyamide,
50. [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [4-isopropylphenyl] carboxyamide,
51. [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-butylphenyl] carboxyamide,
52. [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-rert-butylphenyl] carboxyamide,
53. [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [3 ,4-dimethylphenyl] carboxyamide,
54. [4-(N-hydroxycarbamoyl)phenyl]-N-adamantyl-N-methylcarboxyamide, and
55. N-adamantyl [4-(N-hydroxy-N-methylcarbamoyl)phenyl]-N-methylcarboxyamide.
Hydroxamic acid derivatives of the formula ( I ) obtained in said methods is a retinoid and function as an agonist to retinoic acid receptor and, based on retinoid' s efficacy, can promote collagen biosynthesis and inhibit the expressions of collagenase, i.e. an enzyme for decomposing collagen and of elastase, i.e. an enzyme for decomposing elastin. Therefore, hydroxamic acid derivatives of the formula ( I ) provided by the present invention may be incorporated into medicines or external applications for improving skin elast city.
PREFERRED EMBODIMENT OF THE INVENTION
The methods for preparing hydroxamic acid derivatives according to the present invention will be described in more detail by way of the following examples. However, these examples are provided for the purpose of illustration only and should not be construed as limiting the scope of the invention, which will be apparent to one skilled in the art.
<Example 1> Preparation of N- 4-(N-hydroxycarbamoyl phenyl] benzamide 20.0g (0.16mol) of benzoic acid was dissolved in 250m£ of pyridine and then was cooled in a ice bath of 10°C . Thereto, 23. lg (0.21mol) of ethyl chloroformate was added dropwise for 30 minutes. The mixture was stirred at room temperature for 2 hours and then filtered to remove salts, to give an anhydride (30.2g, 0.15mol). 24.1G (0.16mol) of metyl aminobenzoate was dissolved in 250m£ of pyridine and then was cooled in a ice bath of 10 °C . Thereto, the anhydride formed in the previous step was added dropwise for 30 minutes. The mixture was stirred for another 2 hours. After distillation of the solvent, the residue was dissolved in 300m£ of ethyl acetate. The ethyl acetate solution was washed with 5% hydrochloric acid and with distilled water, dried over magnesium sulfate, decolorized with active charcoal, and then filtered. The filtrate was dried under reduced pressure, to give methyl 4-(phenylcarbonylamino) benzoate (34.7g, 85% yield) as a pale yellow solid. Subsequently, 34.7g of methyl 4-(phenylcarbonylamino) benzoate was dissolved in 500m£ of methanol and thereto 5 Om-β of 10% KOH was added. After stirring for 3 hours, the mixture was neutralized with hydrochloric acid and then filtered, to give an acid compound, 4-(phenylcarbonylamino) benzoic acid (26.2g, 80% yield). 4-(ρhenylcarbonylamino) benzoic acid formed (24. lg, O.lOmol) was dissolved in 200m# of pyridine and then was cooled in a ice bath of 10°C . Thereto, 22.9g (0.13mol) of ethyl chloroformate was added dropwise for 30 minutes. The mixture was stirred at room temperature for 2 hours and then filtered to remove salts, to give an anhydride (38.7g, 0.12mol). 6.9g (O.lOmol) of hydroxylamine hydrochloride was dissolved in lOOmϋ, of pyridine and then was cooled in a ice bath of 10°C . Thereto, the anhydride formed in the previous step was added dropwise for 30 minutes. The mixture was stirred for another 2 hours. After distillation of the solvent, the residue was dissolved in 300m-£ of ethyl acetate. The ethyl acetate solution was washed with 5% hydrochloric acid and with distilled water, dried over magnesium sulfate, decolorized with active charcoal, and then filtered. The filtrate was dried under reduced pressure, to give a final product, N-[4-(N-hydroxycarbamoyl)phenyl] benzamide (16.6g, 65% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMS0-d6): δll.23(s, 1H), 10.39(s, 1H), 9.04(s, 1H), 8.01(m, 5H), 7.64(m, 4H).
<Example 2> Preparation of N- [4-(TS[-hydroxycarbamoyl phenvn [4-methylphenyl] carboxyamide Except that 4-methylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate: hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.20(s, 1H), 10.41(s, 1H), 9.07(s, 1H), 7.94(m, 4H),
7.80(d, 2H, J = 7.8Hz), 7.49(d, 2H, J = 7.8Hz), 2.33(s, 3H).
<Example 3> Preparation of
N- [4-(N-hydroxycarbamoyl)phenyl] [3 -methylphenyl] carboxyamide Except that 3-methylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.2g, 43% yield) as a pale yellow solid. TLC (in ethyl acetate: hexane = 1:1); Rf = 0.50 1H-NMR(DMSO-d6): δll.21(s, 1H), 10.39(s, 1H), 9.05(s, 1H), 7.90(m, 6H), 7.23(m, 2H), 2.40(s, 3H).
<Example 4> Preparation of N-[4-(N-hydroxycarbamoyl phenyl1 4-ethylphenyl] carboxyamide Except that 4-ethylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.4g, 39% yield) as a pale yellow solid. TLC (in ethyl acetate: hexane = 1:4); Rf = 0.54 1H-NMR(DMSO-d6): δll.20(s, 1H), 10.43(s, 1H), 9.05(s, 1H), 7.91(m, 4H), 7.81(d, 2H, J = 7.8Hz), 7.50(d, 2H, J = 7.8Hz), 2.51(m, 2H), 1.19(m, 3H).
<Example 5> Preparation of
N-[4-(N-hvdroxycarbamoyl phenyl] [4-propylphenyll carboxyamide Except that 4-propylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (12.5g, 42% yield) as a pale yellow solid. TLC (in ethyl acetate: hexane = 1:1); Rf = 0.55 1H-NMR(DMSO-d6): δll.23(s, IH), 10.40(s, IH), 9.03(s, IH), 7.92(m, 4H), 7.83(d, IH, J = 7.8Hz), 7.48(d, IH, J = 7.8Hz), 2.60(m, 2H), 1.51(m, 2H), 0.95(m, 3H).
<Example 6> Preparation of
N- [4-flSf-hvdroxycarbamoyf)phenvι] [4-isopropylphenyl] carboxyamide Except that 4-isopropylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (14.3g, 48% yield) as a pale yellow solid. TLC(in ethyl acetate : hexane = 1:1); Rf = 0.50 1H-NMR(DMSO-d6): δll.20(s, IH), 10.41(s, IH), 9.07(s, IH), 7.94(m, 4H), 7.80(d, 2H, J = 7.8Hz), 7.49(d, 2H, J = 7.8Hz), 2.80(m, IH), 1.30(d, 6H, J = 6.9Hz).
<Example 7> Preparation of
N-r4-(N-hydroxycarbamoyl)phenyl] [4-butylρhenyll carboxyamide Except that 4-butylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (12.8g, 41%) yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): 11.20(s, IH), 10.42(s, IH), 9.06(s, IH), 7.94(m, 4H), 7.80(d, 2H, J = 7.8Hz), 7.49(d, 2H, J = 7.8Hz), 2.60(m, 2H), 1.60(m, 2H), 1.41(m, 2H), 0.95(m, 3H).
<Example 8> Preparation of
N- [4-(N-hydroxycarbamoyl phenyl] [4-tert-butylρhenyl] carboxyamide Except that 4-ter -butylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): 11.20(s, IH), 10.41(s, IH), 9.07(s, IH), 7.92(m, 4H), 7.81(d, 2H, J = 7.8Hz), 7.51(d, 2H, J = 7.8Hz), 1.25(s, 9H).
<Example 9> Preparation of N- [4-(N-hvdroxycarbamoyl phenyl] [3 ,4-dimethylphenyl] carboxyamide Except that 3,4-dinιethylbenzoic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δll.23(s, IH), 10.40(s, IH), 9.05(s, IH), 7.93(m, 3H),
7.80(d, 2H, J = 7.8Hz), 7.50(d, 2H, J = 7.8Hz), 2.47(s, 3H), 2.45(s, 3H).
<Example 10> Preparation of
N-[4-(N-hvdroxycarbamoyl)phenvπ adamantyl carboxyamide Except that adamatanecarboxylic acid was used instead of benzoic acid, the same procedure described in Example 1 was performed to give the title compound (16.6g, 65% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δll.22(s, IH), 9.24(s, IH), 8.87(s, IH), 7.76(m, 4H), 1.96(m, 3H), 1.85(m, 6H), 1.64(m, 6H).
<Example 11> Preparation of adamantyl-N- [4-(N-hydroxy-N-methylcarbamoyl phenyl] carboxyamide Except that N-methyl hydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride, the same procedure described in Example 10 was performed to give the title compound (11.2g, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.50 1H-NMR(DMSO-d6): δ9.98(s, IH), 9.12(s, IH), 7.55(m, 4H), 3.09(s, 3H),
1.94(m, 3H), 1.87(m, 6H), 1.62(m, 6H).
<Example 12> Preparation of
N- [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-benzamide Methyl 4-(phenylcarbonylamino) benzoate (34.7g, 0.16mol) obtained in the intermediate step of Example 1 was dissolved in 250ml of N,N-dimethylformamide and then was cooled in a ice bath of 10°C . Thereto sodium hydride (20.7g, 0.16mol) in 50m# of N,N-dimethylformamide was added dropwise. Subsequently, bromomethane (32g, 0.16mol) was added dropwise to this mixture and further stirred for 1 hour. After stirring for another 2 hours, the mixture was distilled to remove the solvent and then the residue was dissolved in 300m£ of ethyl acetate. The ethyl acetate solution was washed with 5% hydrochloric acid and with distilled water, dried over magnesium sulfate, decolorized with active charcoal, and then filtered. The filtrate was dried under reduced pressure, to give methyl 4-(phenylcarbonylamino)-N-methyl-benzoate (33.5g, 85% yield) as a pale yellow solid. The subsequent procedures were the same as described in Example 1, to give the title compound (12.8g, 38% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 :1); Rf = 0.52 1H-NMR(DMSO-d6): δll.23(s, IH), 10.39(s, IH), 9.04(s, IH), 8.01(m, 5H), 7.64(m, 4H), 3.32(s, 3H).
<Example 13> Preparation of
N-[4-(N-hydroxycarbamoyl phenyl] -N-methyl- [4-methylphenyl] carboxyamide Except that methyl 4-[(4-methylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 2 was used, the procedure described in Example 12 was performed to give the title compound (12.2g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δll.21(s, IH), 10.41(s, IH), 9.08(s, IH), 7.94(m, 4H), 7.83(d, 2H, J = 7.8Hz), 7.52(d, 2H, J = 7.8Hz), 3.30(s, 3H), 2.45(s, 3H).
<Example 14> Preparation of N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[3-methylphenyl] carboxyamide Except that methyl 4-[(3-methylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 3 was used, the procedure described in Example 12 was performed to give the title compound (12.2g, 44% yield) as a pale yellow solid. TLC(in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.20(s, IH), 10.43(s, IH), 9.07(s, IH), 7.93(m, 6H), 7.20(m,2H), 3.32(s, 3H), 2.44(s, 3H).
<Example 15> Preparation of N-[4-(N-hydroxycarbamoyl phenyl]-N-methyl-[4-ethylphenyl] carboxyamide Except that methyl 4-[(4-ethylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 4 was used, the procedure described in Example 12 was performed to give the title compound (10.4g, 42% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 :4); Rf = 0.50 1H-NMR(DMSO-d6): δll.20(s, IH), 10.43(s, IH), 9.05(s, IH), 7.91(m, 4H),
7.81(d, 2H, J = 7.8Hz), 7.50(d, 2H, J = 7.8Hz), 3.31(s, 3H), 2.51(m, 2H), 1.40(m, 3H).
<Example 16> Preparation of N-[4-QS[-hydroxycarbamoyl)phenyl1-N-methyl-[4-propylphenyl] carboxyamide Except that methyl 4-[(4-propylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 5 was used, the procedure described in
Example 12 was performed to give the title compound (11.4g, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.55 1H-NMR(DMSO-d6): δll.23(s, IH), 10.40(s, IH), 9.03(s, IH), 7.92(m, 4H),
7.83(d, IH, J = 7.8Hz), 7.48(d, IH, J = 7.8Hz), 3.34(s, 3H), 2.50(m, 2H), 1.51(m,
2H), 0.95(m, 3H).
<Example 17> Preparation of
N-[4-(N-hvdroxycarbamoyl phenyl]-N-methyl-[4-isopropylphenyl] carboxyamide Except that methyl 4-[(4-isopropylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 6 was used, the procedure described in Example 12 was performed to give the title compound (lO.lg, 40% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 :1); Rf = 0.50 1H-NMR(DMSO-d6): δll.20(s, IH), 10.41(s, IH), 9.07(s, IH), 7.94(m, 4H), 7.80(d, 2H, J = 7.8Hz), 7.49(d, 2H, J = 7.8Hz), 3.35(s, 3H), 3.0(m, IH), 1.30(d, 6H, J = 6.9Hz).
<Example 18> Preparation of N-[4-πSf-hvdroxycarbamoyl)phenyl]-N-methyl-[4-butylphenyl] carboxyamide Except that methyl 4-[(4-butylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 7 was used, the procedure described in Example 12 was performed to give the title compound (12. lg, 47% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): 11.23(s, IH), 10.41(s, IH), 9.03(s, IH), 7.92(m, 4H), 7.83(d, 2H, J = 7.8Hz), 7.53(d, 2H, J = 7.8Hz), 3.30(m, 3H), 2.49(m, 2H), 1.60(m, 2H), 1.41(m, 2H), 0.95(m, 3H).
<Example 19> Preparation of
N-r4-(N-hvdroxycarbamoyl phenyl1-N-methyl-[4-fert-butylphenyl] carboxyamide Except that methyl 4-[(4-tert-butylphenyl)carbonylamino] benzoate obtained in the intermediate step of Example 8 was used, the procedure described in Example 12 was performed to give the title compound (ll.lg, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); R = 0.51 1H-NMR(DMSO-d6): 11.21(s, IH), 10.41(s, IH), 9.05(s, IH), 7.90(m, 4H), 7.79(d, 2H, J = 7.8Hz), 7.43(d, 2H, J = 7.8Hz), 3.32(s, 3H), 1.25(s, 9H).
<Example 20> Preparation of
N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[3,4-dimethylphenyl] carboxyamide Except that methyl 4-[(3,4-dimethylρhenyl)carbonylamino] benzoate obtained in the intermediate step of Example 9 was used, the procedure described in Example 12 was performed to give the title compound (12.2g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 : 1); Rf = 0.52 1H-NMR(DMSO-d6): δll.25(s, IH), 10.43(s, IH), 9.07(s, IH), 7.94(m, 3H), 7.82(d, 2H, J = 7.8Hz), 7.49(d, 2H, J = 7.8Hz), 3.30(s, 3H), 2.48(s, 3H), 2.45(s, 3H).
<Example 21> Preparation of
N-[4-( -hvdroxycarbamoyl phenyl] adamantyl-N-methylcarboxyamide Except that methyl 4-(adamantylcarbonylamino) benzoate obtained in the intermediate step of Example 10 was used, the procedure described in Example 12 was performed to give the title compound (12.8g, 38% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δll.20(s, IH), 9.23(s, IH), 7.76(m, 4H), 3.74 (s, 3H), 1.96(m, 3H), 1.85(m, 6H), 1.64(m, 6H).
<Example 22> Preparation of adamantyl-N-[4-('N-hvdroxy-N-methylcarbamoyl phenyn-N-methylcarboxyamid e Except that N-methyl hydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride, the procedure described in Example 21 was performed to give the title compound (11.4g, 39% yield) as a pale yellow solid. TLC(in ethyl acetate : hexane = 1:4); Rf = 0.54 1H-NMR(DMSO-d6): δ9.95(s, IH), 7.57(m, 4H), 3.72(s, 3H), 3.07(s, 3H), 1.94(m, 3H), 1.87(m, 6H), 1.62(m, 6H). <Example 23> Preparation of
N- [4-(N-hydroxycarbamoylmethyl)ρhenyl] benzamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (lO.Og, 39% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δll.23(s, IH), 10.39(s, IH), 9.04(s, IH), 8.01(m, 5H), 7.64(m, 4H), 3.20(s, 2H).
<Example 24> Preparation of
N- [4-(N-hydroxycarbamoylmethyl phenyl] [4-methylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 2 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.52 1H-NMR(DMSO-d6): δll.22(s, IH), 10.41(s, IH), 9.07(s, IH), 7.94(m, 4H), 7.80(d, 2H, J = 7.8Hz), 7.49(d, 2H, J = 7.8Hz), 3.21(s, 2H), 2.45(s, 3H).
<Example 25> Preparation of
N-[4-(N-hydroxycarbamoylmethv phenyl][3-methylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the same procedure described in Example 3 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 : 1); Rf = 0.54 1H-NMR(DMSO-d6): δll.20(s, IH), 10.40(s, IH), 9.04(s, IH), 7.91(m, 6H), 7.22(m, 2H), 3.21(s, 2H), 2.44(s, 3H). <Example 26> Preparation of
N- [4-(N-hydroxycarbamoylmethyl phenyl1 r4-ethylphenyl1 carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 4 was performed to give the title compound (12.9g, 45% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:4); Rf = 0.50 1H-NMR(DMSO-d6): δll.20(s, IH), 10.43(s, IH), 9.05(s, IH), 7.91(m, 4H), 7.81(d, 2H, J = 7.8Hz), 7.50(d, 2H, J = 7.8Hz), 3.21(s, 2H), 2.5 l(m, 2H), 1.40(m, 3H).
<Example 27> Preparation of
N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-propylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 5 was performed to give the title compound (13. lg, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 :1); Rf = 0.55 1H-NMR(DMSO-d6): δll.23(s, IH), 10.40(s, IH), 9.03(s, IH), 7.92(m, 4H), 7.83(d, IH, J = 7.8Hz), 7.48(d, IH, J = 7.8Hz), 3.20(s, 2H), 2.50(m, 2H), 1.51(m, 2H), 0.95(m, 3H).
<Example 28> Preparation of
N- [4-(N-hydroxycarbamoylmethyl phenyl] [4-isopropylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 6 was performed to give the title compound (ll.lg, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.50 1H-NMR(DMSO-d6): δll.20(s, IH), 10.41(s, IH), 9.05(s, IH), 7.93(m, 4H), 7.81(d, 2H, J = 7.8Hz), 7.48(d, 2H, J = 7.8Hz), 3.23(s, 2H), 3.01(m, IH), 1.30(d, 6H, J = 6.9Hz).
<Example 29> Preparation of
N- [4-(N-hvdroxycarbamoylmethyl phenyl] [4-butylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 7 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): 11.22(s, IH), 10.40(s, IH), 9.07(s, IH), 7.91(m, 4H), 7.83(d, 2H, J = 7.8Hz), 7.52(d, 2H, J = 7.8Hz), 3.19(s, 2H), 2.49(m, 2H), 1.60(m, 2H), 1.41(m, 2H), 0.95(m, 3H).
<Example 30> Preparation of
N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-ter^-butylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 8 was performed to give the title compound (12.0g, 42% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): 11.22(s, IH), 10.41(s, IH), 9.06(s, IH), 7.91(m, 4H), 7.83(d, 2H, J = 7.8Hz), 7.52(d, 2H, J = 7.8Hz), 3.20(s, 2H), 1.25(s, 9H).
<Example 31> Preparation of
N- [4-(N-hydroxycarbamoylmethyl)phenyl] [3 ,4-dimethylphenyl] carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 9 was performed to give the title compound (11.9g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 :1); Rf = 0.52 1H-NMR(DMSO-d6): δll.20(s, IH), 10.41(s, IH), 9.05(s, IH), 7.92(m, 3H), 7.80(d, 2H, J = 7.8Hz), 7.47(d, 2H, J = 7.8Hz), 3.21(s, 2H), 2.48(s, 3H), 2.44(s, 3H).
<Example 32> Preparation of N-[4-(N-hvdroxycarbamoylmethyl)phenyl] adamantyl carboxyamide Except that 4-aminophenylacetic acid methylester was used instead of methyl 4-aminobenzoate, the procedure described in Example 10 was performed to give the title compound (11.9g, 44%> yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.52 1H-NMR(DMSO-d6): δll.22(s, IH), 9.25(s, IH), 8.87(s, IH), 7.76(m, 4H),
3.27(s, 2H), 1.96(m, 3H), 1.87(m, 6H), 1.63(m, 6H).
<Example 33> Preparation of
2-[4-(adamantlvcarbonylamino)phenyl]-N-hydroxy-N-methylacetamide Except that N-methyl hydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride, the procedure described in Example 32 was performed to give the title compound (12.8g, 41% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δ9.95(s, IH), 9.12(s, IH), 7.55(m, 4H), 3.27(s, 2H), 3.09(s, 3H), 1.94(m, 3H), 1.84(m, 6H), 1.60(m, 6H).
<Example 34> Preparation of r4-(N-hydroxycarbamoyl)phenyl]-N-benzamide Except that monomethylterephthalate and aniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6):δll.21(s, IH), 10.29(s, IH), 9.10(s, IH), 8.01(m, 4H), 7.60(m, 5H).
<Example 35> Preparation of
[4-(N-hvdroxycarbamoyl phenyn-N-[4-methylphenvn carboxyamide Except that onomethylterephthalate and 4-methylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (11.6g, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.49 1H-NMR(DMSO-d6): δll.20(s, IH), 10.32(s, IH), 9.11(s, IH), 8.10(d, 2H, J
= 7.8Hz), 7.98(d, 2H, J = 7.8Hz), 7.80(m, 4H), 2.44(s, 3H).
<Example 36> Preparation of
[4-(N-hydroxycarbamoyl phenyl]-N-[3-methylphenyl] carboxyamide Except that monomethylterephthalate and 3-methylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in
Example 1 was performed to give the title compound (11.6g, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.49 1H-NMR(DMSO-d6): δll.20(s, IH), 10.32(s, IH), 9.10(s, IH), 8.10(m, 6H),
7.90(m, 2H), 2.42(s, 3H).
<Examρle 37> Preparation of
[4-(N-hydroxycarbamoyl)ρhenyl] -N- [4-ethylphenyl] carboxyamide Except that monomethylterephthalate and 4-ethylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in
Example 1 was performed to give the title compound (12.8g, 45% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.20(s, IH), 10.33(s, IH), 9.09(s, IH), 8.12(d, 2H, J = 7.8Hz), 7.97(d, 2H, J = 7.8Hz), 7.81(m, 4H), 2.53(m, 2H), 1.42(m, 3H).
<Example 38> Preparation of [4-(N-hydroxycarbamoyl phenyl]-N-[4-propylphenyl] carboxyamide Except that monomethylterephthalate and 4-propylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (11.6g, 39% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.53 1H-NMR(DMSO-d6): δll.22(s, IH), 10.33(s, IH), 9.10(s, IH), 8.13(d, 2H, J = 7.8Hz), 7.96(d, 2H, J = 7.8Hz), 7.88(m, 4H), 2.46(m, 2H), 1.50(m, 2H), 0.98(m, 3H).
<Example 39> Preparation of r4-(N-hydroxycarbamoyl phenyl] -N- [4-isopropylphenyl] carboxyamide Except that monomethylterephthalate and 4-isoproρylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (ll.lg, 41% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR (DMSO-d6): δll.20(s, IH), 10.31(s, IH), 9.11(s, IH), 8.11(d, 2H, J = 7.8Hz), 7.99(d, 2H, J = 7.8Hz), 7.8 l(m, 4H), 2.99(m, IH), 1.30(d, 6H, J = 6.9Hz).
<Example 40> Preparation of
[4-(N-hydroxycarbamoyl phenyl] -N- [4-butylphenyl] carboxyamide Except that monomethylterephthalate and 4-butylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (12.8g, 41% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H NMR (DMSO-d6): δll.21(s, IH), 10.33(s, IH), 9.13(s, IH), 8.13(d, 2H,
J = 7.8 Hz), 7.95(d, 2H, J = 7.8Hz), 7.88(m, 4H), 2.50(m, 2H), 2.00(m, 2H), 1.48(m, 2H), 0.95(m, 3H).
<Example 41> Preparation of [4-(N-hydroxycarbamoyl)phenyl]-N-[4-tert-butylphenyl] carboxyamide Except that monomethylterephthalate and 4-tert-butylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (12.8g, 41% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.21(s, IH), 10.31(s, IH), 9.10(s, IH), 8.15(d, 2H, J = 7.8 Hz), 7.94(d, 2H, J = 7.8Hz), 7.85(m, 4H), 1.40(s, 9H).
<Example 42> Preparation of [4-(N-hydroxycarbamoyl phenyl] -N- [3.4-dimethylphenyl] carboxyamide Except that monomethylterephthalate and 3,4-dimethylaniline were used instead of benzoic acid and methyl 4-aminobenzoate, the procedure described in Example 1 was performed to give the title compound (11.6g, 43% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 : 1); Rf = 0.49 1H-NMR (DMSO-d6): δll.20(s, IH), 10.30(s, IH), 9.11(s, IH), 8.10(d, 2H, J = 7.8Hz), 7.98(d, 2H, J = 7.8Hz), 7.84(m, 3H), 2.46(s, 3H), 2.42(s, 3H). <Example 43> Preparation of [4-(N-hydroxycarbamoyl phenyl1 -N-adamantyl carboxyamide Except that monomethylterephthalate and adamantamine were used instead of adamantanecarboxylic acid and methyl 4-aminobenzoate, the procedure described in Example 10 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR (DMSO-d6): δll.20(s, IH), 9.21(s, IH), 8.87(s, IH), 7.73(m, 4H), 1.94(m, 3H), 1.84(m, 6H), 1.62(m, 6H).
<Example 44> Preparation of
N-adamantyl [4-(N-hydroxy-N-methylcarbamoyl phenyl] carboxyamide Except that N-methyl hydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride, the procedure described in Example 43 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 :1); Rf = 0.51 1H-NMR(DMSO-d6): δ9.99(s, IH), 9.10(s, IH), 7.53(m, 4H), 3.10(s, 3H), 1.91(m, 3H), 1.83(m, 6H), 1.60(m, 6H).
<Example 45> Preparation of
[4-(N-hydroxycarbamoyl phenyl]-N-methyl-N-benzamide Except that methyl 4-(ρhenylcarbamoyl) benzoate obtained in the intermediate step of Example 34 was used, the procedure described in Example 12 was performed to give the title compound (12.0g, 40% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 : 1); Rf = 0.51 1H-NMR(DMSO-d6): δll.21(s, IH), 10.29(s, IH), 9.10(s, IH), 8.01(m, 4H), 7.60(m, 5H), 3.20(s, 3H). <Example 46> Preparation of
[4-(N-hydroxycarbamoyl phenyl1 -N-methyl-N- [4-methylphenyl] carboxyamide Except that methyl 4-[(4-methylphenyl)"carbamoyl] benzoate obtained in the intermediate step of Example 35 was used, the procedure described in Example 12 was performed to give the title compound (ll.Og, 39% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.20(s, IH), 10.39(s, IH), 9.11(s, IH), 8.11(d, 2H, J = 7.8Hz), 7.98(d, 2H, J = 7.8Hz), 7.91(m, 4H), 3.20(s, 3H), 2.50(s, 3H).
<Example 47> Preparation of [4-(N-hydroxycarbamoyl phenyl]-N-methyl-N-[3-methylphenyl] carboxyamide Except that methyl 4-[(3-methylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 36 was used, the procedure described in Example 12 was performed to give the title compound (ll.Og, 39% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.21(s, IH), 10.30(s, IH), 9.13(s, IH), 8.10(m, 6H), 7.88(m, 2H), 2.50(s, 3H).
<Example 48> Preparation of [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-ethylphenyl] carboxyamide Except that methyl 4-[(4-ethylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 37 was used, the procedure described in Example 12 was performed to give the title compound (12.0g, 40% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.55 1H-NMR(DMSO-d6): δll.22(s, IH), 10.33(s, IH), 9.10(s, IH), 8.13(d, 2H, J = 7.8Hz), 7.97(d, 2H, J = 7.8Hz), 7.89(m, 4H), 3.20(s, 3H), 2.46(m, 2H), 0.98(m, 3H).
<Example 49> Preparation of [4-(N-hydroxycarbamoyl phenyl] -N-methyl-N- [4-propylphenyl] carboxyamide Except that methyl 4-[(4-propylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 38 was used, the procedure described in Example 12 was performed to give the title compound (12.8g, 41% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1 : 1); Rf = 0.55 1H-NMR(DMSO-d6): δll.20(s, IH), 10.31(s, IH), 9.13(s, IH), 8.12(d, 2H, J = 7.8Hz), 7.96(d, 2H, J = 7.8Hz), 7.89(m, 4H), 3.20(s, 3H), 2.46(m, 2H), 1.50(m, 2H), 0.98(m, 3H).
<Example 50> Preparation of
[4-(N-hydroxycarbamoyl phenyl] -N-methyl-N- [4-isopropylphenyl] carboxyamide Except that methyl 4-[(4-isopropylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 39 was used, the procedure described in Example 12 was performed to give the title compound (13.2g, 44% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.21(s, IH), 10.32(s, IH), 9.15(s, IH), 8.10(d, 2H, J = 7.8 Hz), 7.94(d, 2H, J = 7.8Hz), 7.83(m, 4H), 3.21(s, 3H), 2.50(m, IH), 1.32(d, 6H, J = 6.9Hz).
<Example 51> Preparation of [4-(N-hvdroxycarbamoyl phenyl]-N-methyl-N-[4-butylphenyl] carboxyamide Except that methyl 4-[(4-butylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 40 was used, the procedure described in Example 12 was performed to give the title compound (12.0g, 40% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.20(s, IH), 10.33(s, IH), 9.14(s, IH), 8.12(d, 2H, J = 7.8 Hz), 7.95(d, 2H, J = 7.8Hz), 7.84(m, 4H), 3.22(s, 3H), 2.50(m, 2H), 2.00(m, 2H), 1.48(m, 2H), 0.95(m, 3H).
<Example 52> Preparation of
[4-(N-hydroxycarbamoyl phenyl]-N-methyl-N-[4-tgrt-butylphenyl] carboxyamide Except that methyl 4-[(4-tert-butylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 41 was used, the procedure described in Example 12 was performed to give the title compound (12.5g, 41% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.22(s, IH), 10.33(s, IH), 9.12(s, IH), 8.11(d, 2H, J 7.8 Hz), 7.96(d, 2H, J = 7.8Hz), 7.84(m, 4H), 3.20(s, 3H), 1.24(s, 9H).
<Example 53> Preparation of
[4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [3 ,4-dimethylphenyl] carboxyamide Except that methyl 4-[(3,4-dimethylphenyl)carbamoyl] benzoate obtained in the intermediate step of Example 42 was used, the procedure described in Example 12 was performed to give the title compound (ll.Og, 39% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.20(s, IH), 10.30(s, IH), 9.11(s, IH), 8.11(d, 2H, J = 7.8Hz), 7.95(d, 2H, J = 7.8Hz), 7.94(m, 3H), 3.20(s, 3H), 2.53(s, 3H), 2.50(s, 3H).
<Example 54> Preparation of
[4-(N-hvdroxycarbamoyl phenyn-N-adamantyl-N-methylcarboxyamide Except that methyl 4-(N-adamantyl-N-methylcarbamoyl) benzoate obtained in the intermediate step of Example 43 was used, the procedure described in Example 12 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1:1); Rf = 0.51 1H-NMR(DMSO-d6): δll.22(s, IH), 9.22(s, IH), 7.74(m, 4H), 3.71 (s, 3H), 1.93(m, 3H), 1.83(m, 6H), 1.63(m, 6H).
<Example 55> Preparation of
N-adamantyl [4-(N-hydroxy-N-methylcarbamoyl phenyl]-N-methyl carboxyamide Except that N-methyl hydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride, the procedure described in Example 54 was performed to give the title compound (11.8g, 46% yield) as a pale yellow solid. TLC (in ethyl acetate : hexane = 1: 1); Rf = 0.51 1H-NMR(DMSO-d6): δ9.93(s, IH), 7.59(m, 4H), 3.70(s, 3H), 3.05(s, 3H), 1.92(m, 3H), 1.86(m, 6H), 1.60(m, 6H).
Experimental Example 1> Affinity to retinoic acid receptor This example illustrates affinities of hydroxamic acid derivatives obtained in Examples 1 to 55 to retinoic acid receptor, in comparison with retinol and retinoic acid. Receptor-expression plasmid, pECE-RARα and pECE-RARγ were engineered by the prior method (Mol. Cell. Biol. 1996, 16, 1138-1149). RARE-tk-Luc, i.e. RARE reporter was obtained by inserting RARE fragment from b-RARE-tk-CAT into pGL3 luciferase basic vector. CV-1 cells were obtained from ATCC (American Type Culture Collection). CV-1 cells were seeded into 96-well microtiter plate at 5,000 cells per well and cultured in DMEM (Dulbecco's Modified Eagle's Media) supplemented with 2.5% fetal bovine serum. 24 Hours later, the cells were transfected with lOng of pECE-RARα, lOng of pECE-RARγ, lOOng of reporter plasmid and lOOng of β-galactosidase-expression vector, using LipofectaminPlus (GIBCO BRL, grand island, NY). 24 Hours post-transfection, the cells were treated for 24 hours with hydroxamic acid derivatives of Examples 1-55 or retinol at a final concentration of 10"4M or with retinoic acid at a final concentration of 10"5M, which is 10 times lower concentration than those of the former. [Table 1]
Figure imgf000036_0001
Figure imgf000037_0001
The above results for affinity to retinoic acid receptor indicate that hydroxamic acid derivatives obtained in Examples 1 to 55 can be regarded as retinoid compounds.
Experimental Example 2> Effect on collagen biosynthesis This example illustrates effects of hydroxamic acid derivatives obtained in Examples 1 to 55 on collagen biosynthesis, in comparison with retinol and retinoic acid. Human fibroblasts were seeded into 24-well plate at lxlO5 cells per well and then cultured to 90% of growth. Then, the fibroblastes were cultured in serum-free DMEM for 24 hours and treated with 10"4M of hydroxamic acid derivatives of Examples 1-55, retinol or retinoic acid in serum-free medium, and then incubated in CO2 incubator for 24 hours. For each supernatant, procollagen production was measured with procoUagen type I ELISA kit. The results are shown in Table 2 and collagen biosynthesis was evaluated as a relative value, in consideration that the value of control group with no material treated is 100.
[Table 2]
Figure imgf000038_0001
Figure imgf000039_0001
Experimental Example 3> Inhibition of collagenase expression This example illustrates inhibition by hydroxamic acid derivatives obtained in Examples 1 to 55 of collagenase expression, in comparison with retinol and retinoic acid. Human fibroblasts were seeded into 96-well microtiter plate at 5,000 cells per well and then cultured to 90% of growth in DMEM (Dulbecco's Modified Eagle's Media) supplemented with 2.5% fetal bovine serum. Then, the fibroblastes were cultured in serum-free DMEM for 24 hours and treated for 24 hours with 10'4M of hydroxamic acid derivatives of Examples 1-55, retinol or retinoic acid in serum- free medium, and then the culture fluid was collected. For each culture fluid, collagenase production was measured with collagenase kit (commercialized by AmershamPharmacia Biotech). Firstly, the culture fluid was added to 96-well plate spread with primary collagenase antibody and then antigen-antibody reaction was performed in an incubator for 3 hours. Later, chromophore-conjugated secondary antibody was added to the 96-well plate and then reacted for 15 minutes. Then, color former was added thereto, to induce development at room temperature for 15 minutes. 1M of sulfuric acid was added to stop the reaction. The reaction solution got yellow. The color density depends on the progress of the reaction. The absorbance of the yellow 96-well plate was measured at 405nm using absoφtiometer. Collagenase expression was calculated by the following equation 1. Herein, the absorbance of the culture fluid collected from the medium with no material treated was used as a control.
[Equation 1]
Collagenase expression (%) = (Absorbance of test group with said material treated /Absorbance of control group with no material treated)xl00
The results for inhibition of collagenase expression in the cells are shown in Table 3 and confirmed that hydroxamic acid derivatives of the present invention could inhibit collagenase expression in vitro. Collagenase expression was evaluated as a relative value, in consideration that the value of control group with no material treated is 100.
[Table 3]
Figure imgf000040_0001
Figure imgf000041_0001
Experimental Example 4> Inhibition of elastase expression This example illustrates inhibition by hydroxamic acid derivatives obtained in Examples 1 to 55 of elastase expression, in comparison with retinol and retinoic acid. Human fibroblasts were seeded into 96-well microtiter plate at 5,000 cells per well and then cultured to 90% of growth in DMEM (Dulbecco's Modified Eagle's Media) supplemented with 2.5% fetal bovine serum. Then, the fibroblastes were cultured in serum-free DMEM for 24 hours and treated for 24 hours with 10"4M of hydroxamic acid derivatives of Examples 1-55, retinol or retinoic acid in serum- free medium, and then the culture fluid was collected. For each culture fluid, elastase production was measured with elastase kit (commercialized by AmershamPharmacia Biotech). Firstly, the culture fluid was added to 96-well plate spread with primary elastase antibody and then antigen-antibody reaction was performed in an incubator for 3 hours. Later, chromophore-conjugated secondary antibody was added to the 96-well plate and then reacted for 15 minutes. Then, color former was added thereto, to induce development at room temperature for 15 minutes. 1M of sulfuric acid was added to stop the reaction. The reaction solution got yellow. The color density depends on the progress of the reaction. The absorbance of the yellow 96-well plate was measured at 405nm using absorptiometer. Elastase expression was calculated by the following equation 2. Herein, the absorbance of the culture fluid collected from the medium with no material treated was used as a control.
[Equation 2]
Elastase expression (%) = (Absorbance of test group with said material treated /Absorbance of control group with no material treated)x 100
The results for inhibition of elastase expression in the cells are shown in Table 4 and confirmed that hydroxamic acid derivatives of the present invention could inhibit elastase expression in vitro. Elastase expression was evaluated as a relative value, in consideration that the value of control group with no material treated is 100.
[Table 4]
Figure imgf000042_0001
Figure imgf000043_0001
Experimental Example 5> Primary skin irritation test on animals 1) Method Test was performed using fifty-six (56) of healthy male rabbits whose backs were depilated. The compounds of Examples 1-55 were dissolved in solvent (1,3-butylene glycol: ethanol = 7:3) to give 1% solution of test samples. 0.5ml of the test sample solution was applied to the right site of 2.5cmx2.5cm region on each of the depilated back. Left site with no sample treated was compared as a control. 24 hours or 72 hours later, skin abnormality such as erythema, crust and edema was observed. Skin response was scored according to "standard guide for toxicity test of foods and drugs", as shown in Table 5. Based on the score of skin response, skin irritation was evaluated according to Draize's P.I.I.(Primary Irritation Index) and compared with retinoic acid. The results are shown in Table 6.
[Table 5]
Figure imgf000044_0001
[Table 6]
Figure imgf000044_0002
Example 3 0.375 No irritation Example 31 0.567 No irritation Example 4 0.350 No irritation Example 32 0.375 No irritation Example 5 0.375 No irritation Example 33 0.765 No irritation Example 6 0.315 No irritation Example 34 0.678 No irritation Example 7 0.312 No irritation Example 35 0.245 No irritation Example 8 0.330 No irritation Example 36 0.456 No irritation Example 9 0.470 No irritation Example 37 0.456 No irritation Example 10 0.375 No irritation Example 38 0.567 No irritation Example 11 0.375 No irritation Example 39 0.145 No irritation Example 12 0.410 No irritation Example 40 0.546 No irritation Example 13 0.500 No irritation Example 41 0.367 No irritation Example 14 0.231 No irritation Example 42 0.987 No irritation Example 15 0.789 No irritation Example 43 0.456 No irritation Example 16 0.567 No irritation Example 44 0.678 No irritation Example 17 0.123 No irritation Example 45 0.900 No irritation Example 18 0.321 No irritation Example 46 0.345 No irritation Example 19 0.223 No irritation Example 47 0.367 No irritation Example 20 0.421 No irritation Example 48 0.468 No irritation Example 21 0.345 No irritation Example 49 0.342 No irritation Example 22 0.350 No irritation Example 50 0.234 No irritation Example 23 0.321 No irritation Example 51 0.331 No irritation Example 24 0.321 No irritation Example 52 0.412 No irritation Example 25 0.423 No irritation Example 53 0.321 No irritation Example 26 0.321 No irritation Example 54 0.567 No irritation Example 27 0.568 No irritation Example 55 0.245 No irritation
As shown in Table 6, hydroxamic acid derivatives obtained in Examples 1 to 55 were confirmed to be non-irritative to the skin. These results illustrate that hydroxamic acid derivatives of the present invention have the same efficacy in improving skin elasticity as that of retinol or retinoic acid, and additionally good safety and less skin irritation, to be incorporated into skin-care external compositions for improving skin elasticity.
Experimental Example 6> Phototoxicity test Test was performed for twenty-five (25) of white guinea pigs whose backs were depilated and fixed. On both sides of the back, six(6) sites of 2cmx2cm, three(3) per side were sectioned. Right sites were compared as controls with no irradiation (UV non-irradiation sites) and left sites were irradiated (UV irradiation sites). As a negative control, vehicle of 1,3-butylene glycol:ethanol=7:3 and as a positive control, 0.1% 8-MOP(methoxypsoralene) were prepared, and then hydroxamic acid derivatives of Examples 1-55 were dissolved in 1,3-butylene glycol:ethanol=7:3, to give l%(w/v) of solutions, of which each 50 β was applied. 30 Minutes later, right sites were shielded with aluminum foil and UVA(320-380nm) was irradiated at a distance of about 10cm therefrom using Waldmann to the final energy of 15 J/cm2. After 24, 48 and 72 hours elapsed, skin response of guinea pig was observed. Erythema and edema were scored from 0 to 4, as shown in said Table 5 and skin response was evaluated by the sum of scores. Evaluation was estimated for each elapsed time, i.e. 24, 48 and 72 hours and maximum scores were selected, to calculate irritation index by the following equation 3. Then, phototoxic index was calculated by the following equation 4. The results are shown in Table 7. [Equation 3] Irritation index = (ΣMaximum of erythema + ΣMaximum of edema) / Number of animals
[Equation 4]
Phototoxic index = (Irritation index of UV irradiation site) - (Irritation index of UV non-irradiation site)
[Table 7] Materials Phototoxic index Evaluation Materials Phototoxic index Evaluation Example 1 0 No phototoxicity Example 29 0 No phototoxicity Example 2 No phototoxicity Example 30 No phototoxicity Example 3 No phototoxicity Example 31 No phototoxicity Example 4 No phototoxicity Example 32 No phototoxicity Example 5 No phototoxicity Example 33 No phototoxicity Example 6 No phototoxicity Example 34 No phototoxicity Example 7 No phototoxicity Example 35 No phototoxicity Example 8 No phototoxicity Example 36 No phototoxicity Example 9 No phototoxicity Example 37 No phototoxicity
Example 10 No phototoxicity Example 38 No phototoxicity
Example 11 No phototoxicity Example 39 No phototoxicity
Example 12 No phototoxicity Example 40 No phototoxicity
Example 13 No phototoxicity Example 41 No phototoxicity
Example 14 No phototoxicity Example 42 No phototoxicity
Example 15 No phototoxicity Example 43 No phototoxicity
Example 16 No phototoxicity Example 44 No phototoxicity
Example 17 No phototoxicity Example 45 No phototoxicity
Example 18 No phototoxicity Example 46 No phototoxicity
Example 19 No phototoxicity Example 47 No phototoxicity
Example 20 No phototoxicity Example 48 No phototoxicity
Example 21 No phototoxicity Example 49 No phototoxicity
Example 22 No phototoxicity Example 50 No phototoxicity
Example 23 No phototoxicity Example 51 No phototoxicity
Example 24 No phototoxicity Example 52 No phototoxicity
Example 25 No phototoxicity Example 53 No phototoxicity
Example 26 No phototoxicity Example 54 No phototoxicity
Figure imgf000048_0001
As shown in Table 7, hydroxamic acid derivatives obtained in Examples 1 to 55 were confirmed to have 0 of phototoxic index, which was lower value than 0.5, criterion value to be estimated as no phototoxicity.
Hydroxamic acid derivatives according to the present invention may be incorporated into skin-care external compositions. The present composition may be formulated into, but not limited to, cosmetic compositions such as skin softners, astringents, nutrient toilet water, nutrient creams, massage creams, essences, eye creams, eye essences, cleansing creams, cleansing foams, cleansing water, packs, powders, body lotions, body creams, body oils, body essences, make-up bases, foundations, hairdyes, shampoos, hair-conditioners and body cleansers; and pharmaceutical compositions such as ointment, gels, creams, patches, and sprays. And, each formulation may further contain bases and additives suitable for the preparation thereof, if necessary, whose kind and amount can be easily selected in this art.
Eormulation 1> Nutrient toilet water (Milk lotion) Nutrient toilet water containing said hydroxamic acid derivatives obtained in Examples 1 to 55 was prepared.
Figure imgf000048_0002
Figure imgf000049_0001
Eormulation 2> Nutrient cream Nutrient cream containing said hydroxamic acid derivatives obtained in Examples 1 to 55 was prepared.
Figure imgf000049_0002
Figure imgf000050_0001
Eormulation 3> Massage cream Massage cream containing said hydroxamic acid derivatives obtained in Examples 1 to 55 was prepared.
Figure imgf000050_0002
Eormulation 4> Ointment Ointment containing said hydroxamic acid derivatives obtained in Examples 1 to 55 was prepared.
Figure imgf000050_0003
Figure imgf000051_0001
INDUSTRIAL APPLICATION OF THE INVENTION
As described in the above, hydroxamic acid derivatives according to the present invention can promote collagen biosynthesis and inhibit the expressions of collagenase and elastase by interacting to retinoic acid receptor. Furthermore, they do not cause skin irritation and skin toxicity, which have been drawbacks of retinoid compounds to be solved. Therefore, they can be incoφorated into medicines or skin-care external compositions for improving skin elasticity and preventing skin aging.

Claims

1. A hydroxamic acid derivative represented by the following formula ( I ) [Formula 1]
Figure imgf000052_0001
(I) wherein,
Figure imgf000052_0002
, herein, R5 and R6 each independently represents a hydrogen atom, an alkyl group having from 1 to 10 carbon atoms or a cyclic alkyl group having from 3 to 6 carbon atoms; R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents an alkyl group having from 1 to 10 carbon atoms; R3 is -(CH)n-, herein, n = 0 or 1; and R4 is a hydrogen atom or an alkyl group having from 1 to 10 carbon atoms.
2. The hydroxamic acid derivative according to Claim 1, which is selected from the group consisting of
N- [4-(N-hydroxycarbamoyl)phenyl] benzamide, N-[4-(N-hydroxycarbamoyl)phenyl] [4-methylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl][3-methylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl] [4-ethylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoyl)phenyl] [4-propylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoyl)phenyl] [4-isopropylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl] [4-butylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl] [4-tert-butylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl][3,4-dimethylρhenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl] adamantyl carboxyamide, adamantyl-N- [4-(N-hydroxy-N-methylcarbamoyl)phenyl] carboxyamide, N- [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-benzamide, N-[4-(N-hydroxycarbamoyl)ρhenyl]-N-methyl-[4-methylρhenyl] carboxyamide, N- [4-(N-hydroxycarbamoyl)phenyl] -N-methyl- [3 -methylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-ethylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-propylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-isopropylphenyl] carboxyamide,
N-[4-(N-hydroxycarbamoyl)ρhenyl]-N-methyl-[4-butylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-[4-tert-butylphenyl] carboxyamide,
N- [4-(N-hydroxycarbamoyl)phenyl] -N-methyl- [3 ,4-dimethylphenyl] carboxyamide,
N- [4-(N-hydroxycarbamoyl)phenyl] adamantyl-N-methylcarboxyamide, adamantyl-N-[4-(N-hydroxy-N-methylcarbamoyl)phenyl]-N-methylcarboxyamid e,
N- [4-(N-hydroxycarbamoylmethyl)phenyl] benzamide, N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-methylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoylmethyl)phenyl] [3 -methylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoylmethyl)ρhenyl] [4-ethylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoylmethyl)phenyl] [4-propylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-isopropylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-butylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoylmethyl)phenyl] [4-tert-butylphenyl] carboxyamide, N- [4-(N-hydroxycarbamoylmethyl)phenyl] [3 ,4-dimethylphenyl] carboxyamide, N-[4-(N-hydroxycarbamoylmethyl)phenyl] adamantyl carboxyamide, 2-[4-(adamantylcarbonylamino)phenyl]-N-hydroxy-N-methylacetamide, [4-(N-hydroxycarbamoyl)phenyl]-N-benzamide, [4-(N-hydroxycarbamoyl)phenyl] -N- [4-methylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl] -N- [3 -methylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)ρhenyl]-N-[4-ethylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-[4-propylρhenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-[4-isopropylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-[4-butylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-[4-tert-butylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-[3 ,4-dimethylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl] -N-adamantyl carboxyamide, N-adamantyl [4-(N-hydroxy-N-methylcarbamoyl)phenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-benzamide, [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-methylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[3-methylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-ethylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [4-propylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [4-isopropylphenyl] carboxyamide,
[4-(N-hydroxycarbamoyl)phenyl]-N-methyl-N-[4-butylphenyl] carboxyamide, [4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [4-tert-butylphenyl] carboxyamide,
[4-(N-hydroxycarbamoyl)phenyl] -N-methyl-N- [3 ,4-dimethylphenyl] carboxyamide,
[4-(N-hydroxycarbamoyl)phenyl]-N-adamantyl-N-methylcarboxyamide, and N-adamantyl [4-(N-hydroxy-N-methylcarbamoyl)phenyl]-N-methylcarboxyamide.
3. A method for preparing the hydroxamic acid derivative according to Claim 1, which comprises the steps of: (a) Reacting benzoic acid or adamantanecarboxylic acid with methyl 4-aminobenzoate or 4-aminophenylacetic acid methylester, to produce a benzamide compound;
(b) Substituting an alkyl group for amide bond of benzamide formed in said step;
(c) Hydrolyzing methylester of benzamide or alkyl-substituted benzamide compounds formed in said steps, to produce an acid; and
(d) Reacting said acid with hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride, to produce a hydroxamic acid derivative.
4. A method for preparing the hydroxamic acid derivative according to Claim 1, which comprises the steps of :
(a) Reacting aniline or adamantamine with monomethylterephthalate, to produce a benzamide compound;
(b) Substituting an alkyl group for amide bond of benzamide formed in said step;
(c) Hydrolyzing methylester of benzamide or alkyl-substituted benzamide compounds formed in said steps, to produce an acid; and
(d) Reacting said acid with hydroxylamine hydrochloride or N-methyl hydroxylamine hydrochloride, to produce a hydroxamic acid derivative
5. A skin-care external composition for preventing skin aging, containing the hydroxamic acid derivative according to Claim 1 as an active ingredient.
6. A collagenase expression-inhibiting agent containing the hydroxamic acid derivative according to Claim 1 as an active ingredient.
7. An elastase expression-inhibiting agent containing the hydroxamic acid derivative according to Claim 1 as an active ingredient.
PCT/KR2004/002143 2003-08-26 2004-08-26 Hydroxamic acid derivatives and the method for preparing thereof WO2005019162A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04774404A EP1660437B1 (en) 2003-08-26 2004-08-26 Hydroxamic acid derivatives and the method for preparing thereof
US10/595,124 US7282522B2 (en) 2003-08-26 2004-08-26 Hydroxamic acid derivatives and the method for preparing thereof
JP2006524575A JP4939941B2 (en) 2003-08-26 2004-08-26 Hydroxamic acid derivative and method for producing the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2003-0059177 2003-08-26
KR20030059177 2003-08-26
KR1020040020401A KR100629712B1 (en) 2003-08-26 2004-03-25 Hydroxamic acid derivative having anti-aging activity and preparation method thereof
KR10-2004-0020401 2004-03-25
KR10-2004-0054886 2004-07-14
KR1020040054886A KR100643511B1 (en) 2004-07-14 2004-07-14 Hydroxamic acid derivative and the preparation method thereof

Publications (1)

Publication Number Publication Date
WO2005019162A1 true WO2005019162A1 (en) 2005-03-03

Family

ID=36204434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/002143 WO2005019162A1 (en) 2003-08-26 2004-08-26 Hydroxamic acid derivatives and the method for preparing thereof

Country Status (3)

Country Link
US (1) US7282522B2 (en)
EP (1) EP1660437B1 (en)
WO (1) WO2005019162A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017214A3 (en) * 2004-07-12 2006-06-01 Merck & Co Inc Inhibitors of histone deacetylase
WO2006118380A1 (en) * 2005-04-29 2006-11-09 Amorepacific Corporation Hydroxamic acid derivatives and the preparation method thereof
WO2007037295A1 (en) * 2005-09-29 2007-04-05 Shiseido Company, Ltd. Wrinkling prevention or mitigation with adam inhibitor
JP2011190283A (en) * 2003-12-02 2011-09-29 Ohio State Univ Research Foundation Zn2+-chelating motif-tethered short-chain fatty acid as new class of histone deacetylase inhibitor
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
WO2014139963A1 (en) * 2013-03-13 2014-09-18 Unilever Plc Cosmetic compositions with tricyclodecane amides
US9682028B2 (en) 2013-03-13 2017-06-20 Conopco, Inc. Personal care photoprotective compositions with tricyclodecane amides
US9775793B2 (en) 2013-03-13 2017-10-03 Conopco, Inc. Prolonged delivery of certain fragrance components from personal care compositions

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100457949B1 (en) * 2001-09-24 2004-11-18 주식회사 태평양 Ester compound of 3,4,5-trimethoxy phenylacetic acid, 3,4,5-trimethoxy cinnamic acid or 3,4,5-trimethoxy hydrocinnamic acid and preparation method thereof, and whitening cosmetic composition containing said compound
WO2011058582A1 (en) * 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8546588B2 (en) * 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012019772A1 (en) * 2010-08-12 2012-02-16 Institut De Recherche Pour Le Developpement (I.R.D) Method for treating protozoan parasitic diseases
EP2763531A4 (en) * 2011-10-03 2015-11-18 Univ Columbia Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
EP2826769A1 (en) * 2013-07-18 2015-01-21 Institut de Recherche pour le Développement ( IRD) Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof
WO2015100363A1 (en) 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors
WO2019005064A1 (en) 2017-06-29 2019-01-03 Kimberly-Clark Worldwide, Inc. Antimicrobial composition including a dihydroxamic acid and methods of inhibiting microbial growth utilizing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10182583A (en) * 1996-12-25 1998-07-07 Mitsui Chem Inc New hydroxamic acid derivative
CA2281944C (en) * 1997-02-25 2007-05-15 The Regents Of The University Of Michigan Methods and compositions for preventing and treating chronological aging in human skin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1660437A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011190283A (en) * 2003-12-02 2011-09-29 Ohio State Univ Research Foundation Zn2+-chelating motif-tethered short-chain fatty acid as new class of histone deacetylase inhibitor
WO2006017214A3 (en) * 2004-07-12 2006-06-01 Merck & Co Inc Inhibitors of histone deacetylase
KR100844277B1 (en) * 2005-04-29 2008-07-07 (주)아모레퍼시픽 A hydroxamic acid derivative and the preparation method thereof
EP1874722A1 (en) * 2005-04-29 2008-01-09 Amorepacific Corporation Hydroxamic acid derivatives and the preparation method thereof
US7485750B2 (en) 2005-04-29 2009-02-03 Amorepacific Corporation Hydroxamic acid derivatives and the preparation method thereof
EP1874722A4 (en) * 2005-04-29 2010-03-10 Amorepacific Corp Hydroxamic acid derivatives and the preparation method thereof
CN101166712B (en) * 2005-04-29 2011-08-03 株式会社太平洋 Hydroxamic acid derivatives and the preparation method thereof
WO2006118380A1 (en) * 2005-04-29 2006-11-09 Amorepacific Corporation Hydroxamic acid derivatives and the preparation method thereof
WO2007037295A1 (en) * 2005-09-29 2007-04-05 Shiseido Company, Ltd. Wrinkling prevention or mitigation with adam inhibitor
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
WO2014139963A1 (en) * 2013-03-13 2014-09-18 Unilever Plc Cosmetic compositions with tricyclodecane amides
US20160008249A1 (en) * 2013-03-13 2016-01-14 Conopco, Inc., D/B/A Unilever Cosmetic compositions with tricyclodecane amides
US9682028B2 (en) 2013-03-13 2017-06-20 Conopco, Inc. Personal care photoprotective compositions with tricyclodecane amides
US9775793B2 (en) 2013-03-13 2017-10-03 Conopco, Inc. Prolonged delivery of certain fragrance components from personal care compositions
US9883997B2 (en) 2013-03-13 2018-02-06 Conopco, Inc. Cosmetic compositions with tricyclodecane amides
EA029547B1 (en) * 2013-03-13 2018-04-30 Юнилевер Н.В. Cosmetic compositions with tricyclodecane amides

Also Published As

Publication number Publication date
US20060252834A1 (en) 2006-11-09
EP1660437B1 (en) 2008-10-15
EP1660437A4 (en) 2006-09-20
EP1660437A1 (en) 2006-05-31
US7282522B2 (en) 2007-10-16

Similar Documents

Publication Publication Date Title
EP1660437B1 (en) Hydroxamic acid derivatives and the method for preparing thereof
US8609117B2 (en) Compositions comprising jasmonic acid derivatives and use of the derivatives
EP1166766B1 (en) External preparation compositions
WO1989000157A1 (en) Esters of 13-trans-retinoic acid
DE9321495U1 (en) Hydroxamic acid derivative as a metalloproteinase inhibitor
EP0679628A1 (en) Polyene derivatives, pharmaceutical and cosmetic composition containing them and their use
JPH01156950A (en) Benzoylaminophenoxybutanoic acid derivative having 5d-reductase inhibitory activity, production thereof and drug containing said derivative
US10143667B2 (en) Ceramide-like function imparting agent
US7485750B2 (en) Hydroxamic acid derivatives and the preparation method thereof
EP0679631A1 (en) Biaromatic acetylated, an adamantyl group containing compounds, pharmaceutical and cosmetic compositions containing them and their use
EP0661260A1 (en) New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use
JP2000136109A (en) New 10-hydroxy-2-decenoic acid derivatie, its use for facilitating elimination of dermal rubbish from skin and composition containing the derivative
EP0728739B1 (en) Biaromatic amide derivatives, pharmaceutical and cosmetic compositions containing them and their utilisations
KR100629712B1 (en) Hydroxamic acid derivative having anti-aging activity and preparation method thereof
JP4939941B2 (en) Hydroxamic acid derivative and method for producing the same
JP2000344614A (en) Skin preparation for external use
AU605772B2 (en) Topical prodrugs for treatment of acne and skin diseases
US4863963A (en) Novel cinnamoylamide derivatives
KR100643511B1 (en) Hydroxamic acid derivative and the preparation method thereof
WO2008035904A1 (en) Method for processing 4-substituted benzoic acid derivatives having 3, 4-methylene- or 3,4-ethylenedioxybenzene moiety and the use of the same for antiaging cosmetics
US6291478B1 (en) Compounds of the benzylaminodiacetamide family, compositions comprising them, preparation process and uses
EP0291247A2 (en) Novel cinnamoylamide derivatives
KR100837186B1 (en) Retinoic acid derivative having anti-aging activity and preparation method thereof
KR20180126467A (en) Novel aromatic propinyl compound, pharmaceutical and cosmetic composition containing same, and use thereof
JP2002047261A (en) External preparation composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024139.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004774404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006524575

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004774404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006252834

Country of ref document: US

Ref document number: 10595124

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10595124

Country of ref document: US